New cell therapy tested for patients Who've tried everything else
NCT ID NCT07243366
Summary
This early-stage study is testing a new cell therapy for people with severe, treatment-resistant myasthenia gravis. Doctors will give participants specially engineered immune cells (called CD19-CAR-NK cells) from a donor to see if they are safe and can help control the disease. The main goal is to check for side effects, while also measuring changes in muscle weakness, daily function, and disease-related antibodies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.